BIRB 796 (Doramapimod) (285983-48-4) Description:
Doramapimod, also known as BIRB-796, is a member of the N-pyrazole-N’-naphthly urea class of p38MAPK inhibitors, which binds to the kinase with both slow association and dissociation rates. BIRB -796 has entered clinical trials for the treatment of autoimmune diseases.
Doramapimod is a member of the class of pyrazoles that is an immunomodulator used for treatment of rheumatoid arthritis, Crohn’s disease and psoriasis. It has a role as an immunomodulator and an EC 220.127.116.11 (mitogen-activated protein kinase) inhibitor. It is a member of morpholines, a member of pyrazoles, a member of naphthalenes, a member of ureas and an aromatic ether.
BIRB 796 (Doramapimod) (285983-48-4) Specifications:
|Synonym||BIRB 796; BIRB796; BIRB-796; Doramapimod.|
|Purity||>98% (or refer to the Certificate of Analysis)|
|Solubility||Soluble in DMSO, not in water|
|Storage Temp.||Dry, dark and at 0 – 4 C for short term (days to weeks) or -20 C for long term (months to years).|
|Shelf life||>5 years if stored properly|
|Handling||Protect from air and moisture|
|Application||p38 MAP Kinase Inhibitor X, BIRB 796, CAS 285983-48-4, is a cell-permeable, highly potent, slow binding, high affinity inhibitor of p38a (IC50 = 8 and 97 nM with or without 2 h preincubation).|